Salute e Benessere

IONETIX Produces First Batch of Actinium-225

"Commercial cyclotron-produced Ac-225 is a first, and a pivotal milestone for our alpha isotope program and the radiotherapeutic industry," said David Eve, VP of Medical Affairs at IONETIX. "The demand for alpha emitters is surging and this will allow researchers and drug developers to access these crucial isotopes to support their drug development work." "Commercial cyclotron-produced Ac-225 is a first, and a pivotal milestone for our alpha isotope program and the…
PR Newswire
07/06/2024

ZINZINO AB (PUBL): Zinzino now seeks acquisitions in the US and Asia to increase…

The United States accounts for Zinzino's third largest market share today and is also the leading direct sales market in the world, two decisive factors for why Zinzino is now actively looking to gain more traction in the US. Dag Bergheim Pettersen and his team have not set any specific geographic preferences within the US and are scouting targets on their own, drawing on their large network of contacts without taking financial advice to conduct the search. Dag Bergheim Pettersen does his own…
PR Newswire
07/06/2024

Zealand Pharma announces that Boehringer Ingelheim's survodutide demonstrates…

Company announcement - No. 30 / 2024Zealand Pharma announces that Boehringer Ingelheim's survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosisNews builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%).New data on the secondary endpoint shows up...
Nasdaq GlobeNewswire
07/06/2024

Boehringer Ingelheim's survodutide shows breakthrough improvement in liver…

News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%).New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH. 1 Additional sub-analysis shows up to 64.5% of adults with fibrosis stages F2 and F3 (moderate to advanced scarring) achieved an...
Nasdaq GlobeNewswire
07/06/2024

IMOU Launches New Cordless Camera Cell 3C Series

IMOU wireless security cameras are ideal for outdoor security settings without power. Designed to ensure users spend less money and less time, Cell 3C series are easy to install and features a large 5000mAh battery providing up to 120 days of protection on a single charge. Cell 3C Kit and All In One integrates a 3W solar panel that results in less charging and less security concern, whilst minimizing environmental impact. IMOU wireless security cameras are ideal for outdoor security settings...
PR Newswire
07/06/2024

Potential Add-on Treatment for Patients with Parkinson's Disease: Stimvia…

"We are pleased to share preliminary findings indicating promising results. Patients have reported improvements in both the number of Parkinson's disease symptoms and their overall quality of life. Furthermore, we have observed a notable reduction in resting tremor. While the precise data are still under rigorous evaluation, we remain cautiously optimistic about the potential implications of these outcomes," states Prof.David Skoloudik, MD, Ph.D.,FESO, FEAN, the study's lead and...
PR Newswire
07/06/2024

Department of Health - Abu Dhabi and Novartis to Partner to Advance Genomics…

This collaboration will utilise Abu Dhabi's genomics expertise and its future-forward, agile regulatory framework research hub to collaborate on future clinical research and the generation of RWE. This will include exploration of innovative solutions and genomics research in oncology, cardiovascular disease, and neuroscience. The two will also work together to generate and disseminate evidence to support the awareness and understanding of RLT – a form of precision nuclear medicine that may…
PR Newswire
07/06/2024

Alvotech Announces Strategic Refinancing Agreement

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a strategic refinancing transaction. The financing, led by GoldenTree Asset Management, with participation from other institutional investors (collectively, the “Lenders”), will enable Alvotech (the “Company”) to improve cost of capital, address upcoming debt maturities in 2025 and enhance its financial...
Nasdaq GlobeNewswire
07/06/2024

3 Major Product Releases at 3Shape Discover Event

"Professionals seeking a lower-priced scanner should never compromise on the essentials like accuracy and usability. That's what makes our new TRIOS Core intraoral scanner so exciting. TRIOS Core packs 3Shape core scanning technology and a seamlessly integrated workflow with treatment partners in our most affordable scanner to date," says Jakob Just-Bomholt, 3Shape CEO. "Professionals seeking a lower-priced scanner should never compromise on the essentials like accuracy and…
PR Newswire
07/06/2024

The European Patent Office announces that a Tunisian team has been selected as a…

While studying at the Higher Institute of Medical Technologies of Tunis, the young team developed the MOOVOBRAIN system after one of the team had a family member struck with a sudden disability. This highlighted the urgent need for more adaptable assistive technologies. While studying at the Higher Institute of Medical Technologies ofTunis, the young team developed the MOOVOBRAIN system after one of the team had a family member struck with a sudden disability. This highlighted theurgent...
PR Newswire
07/06/2024

MLB Announces IND Approval by US FDA to Initiate Phase 1 Trial of TML-6, a New…

TML-6 is a novel synthetic curcumin analog. Professor Ih-Jen Su at Southern Taiwan University used a platform of 6 aging and AD biomarkers to screen the 12 compounds from Androscience (San Diego, USA) for AD candidate. Preclinical studies showed that TML-6 (ASC-6) exhibits a multi-target action mechanism for AD, including anti-aging, activation of autophagy (mTOR inhibitor), reducing amyloid accumulation, and anti-inflammation (Figure 1), the efficacy confirmed by 2 AD animal models. TML-6 has a…
PR Newswire
07/06/2024

Insider Information: Nexstim Plc Announces Planned Alzheimer's Collaboration…

Company announcement, Helsinki, 7 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc Announces Planned Alzheimer's Collaboration with Sinaptica Therapeutics, Inc. Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has successfully negotiated and signed a Letter of Intent (LOI) to exclusively collaborate with Sinaptica Therapeutics, Inc. (“Sinaptica”) to develop, manufacture and supply Sinaptica's patented precision neuromodulation system custom-based…
Nasdaq GlobeNewswire
07/06/2024

ELFBAR and LOST MARY to Unveil New Innovations at Dubai World Vape Show 2024

The brands will also leverage the trade fair to explore new partnership opportunities with distributors and retailers worldwide. The brands will also leverage the trade fair to explore new partnership opportunities with distributors and retailers worldwide. The occasion marks LOST MARY's office premiere in the UAE market. LOST MARY is now one of the leading vape brands globally in dozens of markets. Since their inception in 2018 and 2021, ELFBAR and LOST MARY have been at the forefront of...
PR Newswire
07/06/2024

Ipsen and Marengo Therapeutics announce second strategic partnership to advance…

Using Marengo's TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaborationResearch will focus on using Marengo's TriSTAR platform to reinvigorate and mobilize selective Vβ T cells to boost anti-tumor activity in patients with traditionally difficult-to-treat 'cold' tumorsPARIS, FRANCE, and CAMBRIDGE, MA, U.S., 07 June 2024 -Ipsen (Euronext: IPN; ADR: IPSEY) and Marengo...
Nasdaq GlobeNewswire
07/06/2024

Kanazawa University research: Sensing a biomarker

The procedure presented by Biyani and colleagues is new in two ways. The first is that it uses newly identified aptamers as molecules that can recognize and capture ADAR1. Aptamers are molecules consisting of sequences of (synthetic) DNA, RNA or other biomolecules that bind to a particular target molecule, in this case ADAR1. The second novelty lies in the use of a field-deployable electrochemical sensor DEPSOR (BioSeeds Corp.), which has the advantages of, apart from being fast and…
PR Newswire
07/06/2024

BioSenic announces 2023 full year results

PRESS RELEASE - REGULATED INFIRMATION BioSenic stopped the patient recruitment for its Phase 2b ALLOB trial in mid-2023.BioSenic has prepared a global restructuring plan covering the years 2024-2032 and will actively pursue follow-up actions.BioSenic expects to use the proceeds from anticipated future fundraising as a priority to progress its Phase 3 clinical trial in cGvHD.Mont-Saint-Guibert, Belgium, June 6, 2024, 9:00pm CEST –BIOSENIC (Euronext Brussels and Paris: BIOS),...
Nasdaq GlobeNewswire
06/06/2024

Ipsen - Monthly information relative to the total number of voting rights and…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1) 31 May 2024 83,814,526 ...
Nasdaq GlobeNewswire
06/06/2024

Market update : FOCUS-27 transformation project financing

Press releaseParis – June 6, 2024 –EUROAPI informs that it has decided to be assisted by amandataire ad hocin its discussions initiated in February 2024 regarding the mid-term and long-term financing of its FOCUS-27 strategic transformation project. Themandat ad hocis an amicable procedure launched at the company's initiative and conducted within a confidential and legally secured framework.EUROAPI has appointed such an independent third party proactively to accelerate the...
Nasdaq GlobeNewswire
06/06/2024

Pharmaceutical Processing and Packaging Equipment Market to be Worth $28.75…

Pharmaceutical processing and packaging equipment are used in the processing and packaging of pharmaceuticals. The processing equipment includes granulation equipment, coating equipment, milling equipment, agitators, purification systems, sterilization equipment, compression equipment, and the packaging equipment includes filling equipment, labeling and serialization, and wrapping equipment. Pharmaceutical processing and packaging equipment are used in the processing and packaging of…
PR Newswire
06/06/2024

Three in four (74%) UK adults experience 'Inattentional Blindness' and could be…

To demonstrate just how many people are missing things right in front of them, giffgaff unveiled the world's biggest ever magic eye[1] in London. Located in Shoreditch, the one-of-a-kind artwork contained the hidden message 'Seeing things more clearly?' in a bid to get the nation to notice the great phone and monthly airtime deals that are passing them by, due to them not paying attention to what's around them. To demonstrate just how many people are missing things right in front of them,...
PR Newswire
06/06/2024

Exoskeleton Market to be Worth $11.90 Billion by 2031 - Exclusive Report by…

The growth in this market is mainly driven by factors such as growing demand for exoskeletons for orthopedic rehabilitation, increasing prevalence of stroke and associated disabilities, and growing investments in exoskeletons by the military & defense sectors. In addition, the replacement of conventional prosthetics with exoskeleton technology and the rising adoption of human augmentation technology in manufacturing and other end-use sectors are expected to provide opportunities for the…
PR Newswire
06/06/2024

Dental Consumables Market Worth $54.6 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=699 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=699 Browse in-depth TOC on "Dental Consumables Market" 850 - Tables 70 - Figures 800 - Pages Dental Consumables Market Scope: Dental restoration segment is expected to account for the largest share, by product in the dental consumables market during the forecast period. Based on...
PR Newswire
06/06/2024

HUBLOT AND DANIEL ARSHAM REDEFINE THE POCKET WATCH WITH THE ARSHAM DROPLET

Inspired by the organic, fluid forms found in nature, the Arsham Droplet represents a true milestone in the world of horology. This collaboration is a testament to the shared commitment of both Hublot and Arsham to creating truly exceptional and transformative experiences that challenge the status quo. Inspired by the organic, fluid forms found in nature, the Arsham Droplet represents a true milestone in the world of horology. This collaboration is a testament to the shared commitment of both...
PR Newswire
06/06/2024

Successful Separation Surgery Gives Hope to Filipina Conjoined Twins in Riyadh

The surgery was led by the esteemed Dr. Abdullah Al Rabeeah, Supervisor General of KSrelief and a distinguished pediatric surgeon with over 30 years of experience. Dr. Al Rabeeah has successfully overseen 60 separation surgeries, and the programme has reviewed 136 cases from 26 different countries since the program's inception in 1990. This year alone, Dr. Al Rabeeah has performed four successful separation surgeries. The surgery was led by the esteemed Dr.Abdullah Al Rabeeah, Supervisor...
PR Newswire
06/06/2024
Altri  Comunicati